Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Corpus Striatum (drug effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Corpus Striatum (cytology) < Corpus Striatum (drug effects) < Corpus Striatum (embryology)  Facettes :

List of bibliographic references indexed by Corpus Striatum (drug effects)

Number of relevant bibliographic references: 55.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000493 (2014) Naomi P. Visanji [Canada]Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia.
001579 (2011) Elisa Garbayo [Espagne] ; Eduardo Ansorena [Espagne] ; Jose Luis Lanciego [Espagne] ; María Jose Blanco-Prieto [Espagne] ; María S. Aymerich [Espagne]Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's disease
001645 (2011) Marios Politis [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; Kit Wu [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; Oliver Pogarell [Allemagne] ; David J. Brooks [Royaume-Uni] ; Anders Bjorklund [Suède] ; Olle Lindvall [Suède] ; Paola Piccini [Royaume-Uni]Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio
001E74 (2010) Pauline Belujon [États-Unis] ; Daniel J. Lodge [États-Unis] ; Anthony A. Grace [États-Unis]Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment
002344 (2009) Wassilios Meissner [France] ; Frédéric Macia [France] ; Alexandra Foubert-Samier [France] ; Martine Guyot [France] ; Emmanuel Bussy [France] ; Michèle Allard [France] ; François Tison [France]Dopamine transporter binding is reduced following disulfiram‐induced striatal damage
002784 (2008) C. Warren Olanow [États-Unis]Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions
002925 (2008) Mario Zappia [Italie] ; Aldo Quattrone [Italie]Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa?
002A93 (2007) Jan Zijlmans [Royaume-Uni, Pays-Bas] ; Andrew Evans [Royaume-Uni] ; Flavia Fontes [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Svetoslav Gacinovic [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Durval Costa [Royaume-Uni, Portugal][123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease
002B58 (2007) Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada]Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia
002E17 (2007) Nadia Stefanova [Autriche] ; Martin Köllensperger [Autriche] ; Monika Hainzer [Autriche] ; Angela Cenci [Suède] ; Werner Poewe [Autriche] ; Gregor Karl Wenning [Autriche]High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence
003245 (2006) Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin
003458 (2006) Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France]Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease
003605 (2006) Petia S. Dimova [Bulgarie] ; Veneta Bojinova [Bulgarie] ; Dimitar Georgiev [Bulgarie] ; Ivan Milanov [Bulgarie]Acute reversible parkinsonism in Epstein–Bbarr virus–related encephalitis lethargica‐like illness
003948 (2005) Michelle Porritt [Australie] ; Davor Stanic [Australie] ; David Finkelstein [Australie] ; Peter Batchelor [Australie] ; Sharon Lockhart [Australie] ; Andrew Hughes [Australie] ; Renate Kalnins [Australie] ; David Howells [Australie]Dopaminergic innervation of the human striatum in Parkinson's disease
003C69 (2004) C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie]Levodopa in the treatment of Parkinson's disease: Current controversies
003F75 (2003) P. K. Morrish [Royaume-Uni]REAL and CALM: What have we learned?
004134 (2003) Daphna Joel [Israël] ; Liat Ayalon [Israël] ; Ricardo Tarrasch [Israël] ; Ina Weiner [Israël]Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: A potential novel treatment in a rat model of Huntington's disease
004280 (2002) Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni]Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
004406 (2002) Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France]Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats
004745 (2001) Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan
004836 (2001) Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie]Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Corpus Striatum (drug effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Corpus Striatum (drug effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Corpus Striatum (drug effects)
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024